936 related articles for article (PubMed ID: 25311217)
1. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
2. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
Efstathiou E; Davis JW; Pisters L; Li W; Wen S; McMullin RP; Gormley M; Ricci D; Titus M; Hoang A; Zurita AJ; Tran N; Peng W; Kheoh T; Molina A; Troncoso P; Logothetis CJ
Eur Urol; 2019 Oct; 76(4):418-424. PubMed ID: 31176622
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Enzalutamide Prior to Prostatectomy.
Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME
Clin Cancer Res; 2017 May; 23(9):2169-2176. PubMed ID: 28151719
[No Abstract] [Full Text] [Related]
6. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
7. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Zang T; Taplin ME; Tamae D; Xie W; Mesaros C; Zhang Z; Bubley G; Montgomery B; Balk SP; Mostaghel EA; Blair IA; Penning TM
Endocr Relat Cancer; 2017 Aug; 24(8):393-404. PubMed ID: 28663228
[TBL] [Abstract][Full Text] [Related]
8. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Qi N; Mao L
Cancer Med; 2023 Feb; 12(4):4352-4356. PubMed ID: 36106643
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
12. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
McKay RR; Xie W; Ye H; Fennessy FM; Zhang Z; Lis R; Calagua C; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang PK; Wagner AA; Parsons JK; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
J Urol; 2021 Jul; 206(1):80-87. PubMed ID: 33683939
[TBL] [Abstract][Full Text] [Related]
13. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Nikitas J; Rettig M; Shen J; Reiter R; Lee A; Steinberg ML; Valle LF; Sachdeva A; Romero T; Calais J; Czernin J; Nickols NG; Kishan AU
Eur Urol; 2024 Jun; 85(6):517-520. PubMed ID: 38494380
[TBL] [Abstract][Full Text] [Related]
14. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
15. Re: Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taneja SS
J Urol; 2015 Jun; 193(6):1983. PubMed ID: 25986794
[No Abstract] [Full Text] [Related]
16. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
17. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
18. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
[TBL] [Abstract][Full Text] [Related]
19. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
